Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
New immunization research from Veterans Affairs Medical Center discussed
October 22nd, 2008
Research findings, 'Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia,' are discussed in a new report. According to recent research published in the Journal of Infectious Diseases, "Controversy persists over the benefits of pneumococcal polysaccharide vaccine (PPV) for adults at high risk for pneumococcal disease. We studied PPV, protein-conjugate pneumococcal vaccine (PCV), and immunologic 'priming' with PCV followed by 'boosting' with PPV in adults who had recovered from pneumococcal pneumonia." "Subjects received PPV followed by PCV 6...
Source: Vaccine Weekly (2008-10-22)
|
